Core Viewpoint - The study identifies CRTAM as a new target that can mitigate the toxicity of immune checkpoint inhibitors (ICB) without compromising their antitumor efficacy [4][9]. Group 1: Research Findings - The research published in Nature Cancer reveals that inhibiting CRTAM can reduce the toxicity associated with immune checkpoint inhibitors while maintaining their effectiveness against tumors [4][9]. - The research team integrated transcriptomic and pharmacovigilance data to analyze the efficacy-toxicity balance mechanism of immune checkpoint inhibitors, establishing CRTAM as a checkpoint for immune-related adverse events (irAE) [7]. - Preclinical models demonstrated that knocking out the Crtam gene or T cell lineage-specific Crtam knockout effectively suppresses the occurrence of irAE [7]. Group 2: Mechanism of Action - CRTAM⁺ T cells preferentially infiltrate normal tissues rather than tumor tissues through interaction with CRTAM-cell adhesion molecule-1, promoting a type 3 immune response centered around IL-23 [7]. - In models of irAE, inhibiting CRTAM can reduce toxic reactions while preserving the tumor microenvironment necessary for therapeutic efficacy [7]. Group 3: Monitoring and Implications - Quantitative detection of CRTAM-type 3 immune axis indicators in blood samples can facilitate monitoring of irAE in patients undergoing treatment with immune checkpoint inhibitors [7]. - The establishment of CRTAM as a T cell checkpoint for irAE provides a potential target for decoupling efficacy and toxicity in immunotherapy [9].